NASDAQ:VKTXViking Therapeutics Stock Price, Forecast & News

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VKTX shares have increased by 58.8% and is now trading at $8.05. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viking Therapeutics.

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Viking Therapeutics.

Viking Therapeutics Inc (NASDAQ:VKTX) issued its quarterly earnings data on Thursday, April, 30th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.01. View Viking Therapeutics' earnings history.

12 analysts have issued 1-year target prices for Viking Therapeutics' shares. Their forecasts range from $9.00 to $25.00. On average, they expect Viking Therapeutics' share price to reach $14.56 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price. View analysts' price targets for Viking Therapeutics.

Headlines about VKTX stock have trended positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Viking Therapeutics earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutViking Therapeutics.

Viking Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 12,440,000 shares, a drop of 8.7% from the April 30th total of 13,620,000 shares. Based on an average daily trading volume, of 1,600,000 shares, the short-interest ratio is currently 7.8 days. Currently, 17.6% of the company's shares are sold short. View Viking Therapeutics' Current Options Chain.

Some companies that are related to Viking Therapeutics include Ra Pharmaceuticals (RARX), Karuna Therapeutics (KRTX), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Pacira Biosciences (PCRX), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH), Corcept Therapeutics (CORT), Xencor (XNCR), IGM Biosciences (IGMS) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Energy Transfer LP Unit (ET), Micron Technology (MU), Crispr Therapeutics (CRSP) and SCYNEXIS (SCYX).

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Viking Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (12.16%), BlackRock Inc. (6.54%), State Street Corp (5.02%), Park West Asset Management LLC (2.20%), Fiera Capital Corp (1.64%) and Geode Capital Management LLC (1.33%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc and Michael Morneau. View institutional ownership trends for Viking Therapeutics.

VKTX stock was sold by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, Morgan Stanley, WINTON GROUP Ltd, Rafferty Asset Management LLC, L & S Advisors Inc, Alps Advisors Inc., Blair William & Co. IL, and Victory Capital Management Inc.. View insider buying and selling activity for Viking Therapeutics.

VKTX stock was bought by a variety of institutional investors in the last quarter, including Aviva PLC, DAFNA Capital Management LLC, JPMorgan Chase & Co., Bailard Inc., SG Americas Securities LLC, Federated Hermes Inc., Thrivent Financial for Lutherans, and Geode Capital Management LLC. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton, and Lawson Macartney. View insider buying and selling activity for Viking Therapeutics.

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VKTX stock can currently be purchased for approximately $8.05.

Viking Therapeutics has a market capitalization of $584.43 million. The biotechnology company earns $-25,780,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Viking Therapeutics employs 17 workers across the globe.

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]